TORONTO, Sept. 20, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a leader in specialized, analysis-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received Organic Certification from Pro-Cert Organic Systems Ltd. (“Pro-Cert”). Pro-Cert is 1 of North America’s top certifiers of organic goods and is accredited by IOAS to supply third celebration certification to the Canadian Organic Requirements.
Organic certification is a sturdy validation of MediPharm Labs’ robust good quality management technique and GMP compliant facility. This certification additional expands the Company’s capabilities to generate bulk wholesale organic extracts and oil for use as an ingredient in finished cannabis concentrate derivatives such as edibles, extracts, topicals and oil goods that will be sold in the Company’s wholesale and retail channels for each healthcare and adult-use markets.
With the growing demand for higher good quality, differentiated goods, MediPharm Labs has once again expanded its capabilities to allow our buyers, and other non-cannabis CPG brands, to introduce revolutionary and premium, larger margin derivative goods in further categories to the Canadian cannabis marketplace.
Pat McCutcheon, CEO of MediPharm Labs
We are proud to get this certification which additional adds third-celebration validation of our good quality management technique and integrity in the provide chain. We sustain our commitment to environmental sustainability as we continue to focus on delivering diversified item offerings to improve the healthcare- and adult-use customer expertise.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and sophisticated derivative goods using a Great Manufacturing Practices made facility and ISO regular constructed clean rooms. MediPharm Labs has invested in an professional, analysis driven group, state-of-the-art technologies, downstream purification methodologies and goal-constructed facilities with 5 major extraction lines obtaining 300,000 kg of annual processing capacity to provide pure, protected and precisely dosed cannabis goods for its buyers. Via its wholesale, white label and tolling platforms, they formulate, course of action, package and distribute cannabis extracts and sophisticated cannabinoid-primarily based goods to domestic and international markets. As a international leader, the Business also completed its 1st industrial export to Australia in June 2019 and is nearing completion of its Australian extraction facility anticipated in 2019 with 75,000 kg of annual processing capacity.
For additional facts, please get in touch with:
Laura Lepore, VP, Investor Relations
Phone: 705-719-7425 ext 216
E-mail: [email protected]
Web page: www.medipharmlabs.com
Original press release